| Literature DB >> 25984140 |
Akio Yamada1, Yoshikazu Tsuji2, Yuich Kato3, Norishi Ueda4.
Abstract
Entities:
Year: 2011 PMID: 25984140 PMCID: PMC4421588 DOI: 10.1093/ndtplus/sfq209
Source DB: PubMed Journal: NDT Plus ISSN: 1753-0784
Fig. 1.(A): The cranial computed tomography (CT) at 1 month of age reveals calvarial hypoplasia, including hypoplasia of temporal bones. (B): A renal biopsy at 3 months of age reveals poor differentiation between proximal and distal convoluted tubules and increased intertubular mesenchyme. Most tubules were small, collapsed, and surrounded by connective tissue. Some dilated tubules and tubular necrosis are noted. There are some dilated Bowman>'s capsules, lacking the glomerular tuft (magnification ×100, Periodic Acid-Schiff staining).
Review of infants with hypocalvaria and/or RTD after intrauterine exposure to the agents that inhibit RASa
| Case | Clinical feature | Inhibitors of RAS | Renal histopathology | Outcome | References |
| 1 | ARF, IGR, deformities of hand and foot, oligohydramnios, PH, RD, small calvarial bones | Captopril | RTD, dilated Bowman’s capsules | Died after birth | [ |
| 2 | ARF, RD, small calvarial plates | Lisinopril | RTD, dilated Bowman’s capsules | Survived with PD | [ |
| 3 | ARF, IGR, large fontanels, oligohydramnios, PH, RD, short arms and legs, widened sutures | Enalapril | RTD, dilated Bowman’s capsules | Died after birth | [ |
| 4 | Deformities of limbs and face, HC, oligohydramnios, PH | Losartan | NA | Fetal death | [ |
| 5 | HC, oligohydramnios | Losartan | NA | Survived with normal renal function | [ |
| 6 | ARF, HC, limb deformities, oligohydramnios, RD | Valsartan | NA | Survived with normal renal function | [ |
| 7 | ARF, HC, oligohydramnios, RD (present case) | Olmesartan medoxomil | RTD, dilated Bowman’s capsules, lacking glomerular tuft | Survived with PD |
ARF, acute renal failure; HC, hypocalvaria; IGR, intrauterine growth restriction; NA, not available; PD, peritoneal dialysis; PH, pulmonary hypoplasia; RAS, renin-angiotensin system; RD, respiratory distress; RDT, renal tubular dysgenesis.
Angiotensin-converting enzyme inhibitors.
Angiotensin II type-I receptor blocker.